WO2007015871A1

WO2007015871A1 - Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Info

Publication number: WO2007015871A1
Application number: PCT/US2006/027878
Authority: WO
Inventors: Paul W. Manley; Wen-Chung Shieh; Paul Allen Sutton; Piotr H. Karpinski; Raeann Wu; Stéphanie MONNIER; Jörg Brozio
Original assignee: Novartis Ag; Novartis Pharma Gmbh
Priority date: 2005-07-20
Filing date: 2006-07-18
Publication date: 2007-02-08
Also published as: IL187787A0; RU2008105827A; TWI455934B; TW200800950A; ES2634291T3; AU2010241419A1; HRP20110639T1; SI1910336T1; CA2823946C; CA2823946A1; HK1116778A1; NZ591142A; US20140038994A1; RU2011120363A; PL1910336T3; CY1111772T1; US8163904B2; EP1910336B1; US8580806B2; MA29686B1

Abstract

Salts of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.

Description

SALTS OF 4 METHYL-N-f3-(4-METHYL-IMIDAZOL-l-YL)-5- TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2- YLAMINO)-

BENZAMIDE

This application claims the benefit of U.S. Provisional Patent Application No. 60/701,406, filed July 20, 2005, the entire disclosure of which is incorporated by reference herein.

Background of the Invention

Field of the Invention

[0001] This invention relates to salts of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, as well as to methods of making the same, pharmaceutical compositions comprising the same and methods of treatment using the same.

Related Background Art

[0002] The compound 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3- (4-pyridm-3-yl-pyrimidin-2-ylamino)-benzamide of the formula

is described in WO 2004/005281 Al. Valuable pharmacological properties are attributed to this compound; thus, it can be used, for example, as a protein kinase inhibitor useful in therapy for diseases which respond to inhibition of protein kinase activity. WO 2004/005281 Al does not disclose any specific salts or salt hydrates or solvates of 4-methyl-N-[3-(4- methyl-imidazol-l-yl)-5-trifluoromethyl-ρhenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)- benzamide.

Summary of the Invention

[0003] The present invention is directed to salts of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)- 5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide. Preferred embodiments of the present invention are directed to the hydrochloride, monophosphate, diphosphate, sulfate, methane sulfonate, ethane sulfonate, benzene sulfonate and p-toluene sulfonate salts of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide.

[0004] The present invention is further directed to a method of preparing a variety of crystalline salts of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridm-3-yl-pyrimidin-2-ylamino)-benzamide comprising the step of: reacting 4-methyl-N- [3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)-benzamide free base with an acid of formula HB in a solvent.

[0005] The invention is further directed to pharmaceutical compositions comprising:

(a) a therapeutically effective amount of a salt of 4-methyl-N-[3-(4-methyl-imidazol- l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; and

(b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient.

[0006] The present invention is also directed to a method of treating a disease which responds to an inhibition of protein kinase activity comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a salt of 4-methyl-N- [3-(4-methyl-imidazol-l-yl)-5-trifluoiOmethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)-benzamide. Brief Description of the Drawings

[0007] Figure 1 shows the x-ray powder diffraction patterns (XRPDs) for forms A and B of the hydrochloride salt of 4-raethyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenylj- 3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide.

[0008] Figure 2 shows the x-ray powder diffraction pattern (XRPD) for the monophosphate salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin~2-ylarnmo)-benzamide.

[0009] Figure 3 shows the x-ray powder diffraction pattern for the diphosphate salt of 4- methyl-N-[3-(4-metliyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide.

[0010] Figure 4 shows the x-ray powder diffraction patterns for forms A and B of the sulfate salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide.

[0011] Figure 5 shows the x-ray powder diffraction pattern for the methane sulfonate (mesylate) salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide.

[0012] Figure 6 shows the x-ray powder diffraction pattern for the ethane sulfonate salt of 4- metliyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzarnide.

[0013] Figure 7 shows the x-ray powder diffraction pattern for the benzene sulfonate salt of

4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide.

[0014] Figure 8 shows the x-ray powder diffraction pattern for the p-toluene sulfonate salt of

4-methyl-N-[3-(4-metliyl-imidazol-l-yl)-5-trifluoiOmethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide. - A -

Detailed Description of the Invention

[0015] The present invention is directed to salts of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)- 5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; prefeiτed embodiments of those salts are described below. Generally, as used herein, "salt" refers to a compound prepared by the reaction of an organic acid or base drug with a pharmaceutically acceptable mineral or organic acid or base; as used herein, "salt" includes hydrates and solvates of salts made in accordance with this invention. Exemplary pharmaceutically acceptable mineral or organic acids or bases are as listed in Tables 1-8 in Handbook of Pharmaceutical Salts, P.H. Stahl and CG. Wermuth (eds.), VHCA, Zurich, pp. 334-345 (2002). As used herein, "polymorph" refers to a distinct "crystal modification" or "polymorphic form" or "crystalline form", which differs from another with respect to x-ray powder diffraction pattern, physicochemical and/or pharmacokinetic properties, and thermodynamic stability. Co-pending U.S. Patent Application No. 60/701,405 (Attorney Docket No. 4-34384), filed concurrently herewith, addresses the various polymorphic forms of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide and salts thereof; the disclosure of that co-pending application is incorporated in its entirety by reference herein.

[0016] The first embodiment of the present invention is directed to the hydrochloride salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide. The hydrochloride salt (form B, monohydrate) is reproducibly produced from methanol when one equivalent hydrochloric acid is used. It is hygroscopic (when first tested, moisture uptake was up to 2% at 60% relative humidity and up to 2.7% at 95% relative humidity, though subsequent testing has shown even greater moisture uptake). It is very slightly soluble in water and slightly soluble in 0.1 N HCl, ethanol and 2-propanol. When tested with thermogravimetric analysis (TGA), two weight loss stages occur. The first stage (onset at about 80°C) represents dehydration, and the second stage weight loss (at about 173°C) represents the loss of HCl (decomposition). Its crystal structure ranges from good to excellent, it becomes amorphous upon grinding and it can withstand compression. The hydrochloride salt is stable at room temperature in standard equilibration tests. Other polymorphic forms of the hydrochloride salt, i.e., forms A, A', A", B', S_B, SB', C, C, Sc, D, and S_E, were also isolated. The XRPD pattern for forms A and B of the hydrochloride salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are shown in Figure 1.

[0017] The second embodiment of the present invention is directed to the monophosphate salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide. The H₃PO₄ mono-salt is reproducibly produced from methanol when one equivalent phosphoric acid is used. The weight loss (room temperature to 200°C) is about 0.29%, and the sample melts at about 208⁰C and decomposes at about 212°C. Its crystal structure is excellent. The XRPD pattern for the monophosphate salt of 4-methyl- N-[3-(4-metliyl-imidazol-l-yl)-5-trifluoromethyl"phenyl]-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)-benzamide is shown in Figure 2.

[0018] The third embodiment of the present invention is directed to the diphosphate salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide. The H₃PO₄ di-salt can be produced from methanol when two equivalents phosphoric acid are used. The weight loss (room temperature to 200⁰C) is about 0.2%, and the sample decomposes at about 21O⁰C. The XRPD pattern for the diphosphate salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide is shown in Figure 3.

[0019] The fourth embodiment of the present invention is directed to the sulfate salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide. The H₂SO₄ salt (form B) is reproducibly produced from methanol when one equivalent sulfuric acid is used. The weight loss (room temperature to 200⁰C) is about 0.15%, and the sample melts with decomposition at about 206⁰C. Its crystal structure ranges from poor to good. One other form (form A) and an amorphous form were isolated. The XRPD patterns for forms A and B of the sulfate salt of 4-methyl-N-[3-(4- methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)- benzamide are shown in Figure 4. [0020] The fifth embodiment of the present invention is directed to the methane sulfonate (mesylate) salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide. This salt is reproducibly produced from ethyl acetate when one equivalent methane sulfonic acid is used. The weight loss (room temperature to 150°C) is about 0.44%, and the sample melts at about 160°C and decomposes at about 26O⁰C. Its crystal structure is poor. The XRPD pattern for the methane sulfonate salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide is shown in Figure 5.

[0021] The sixth embodiment of the present invention is directed to the ethane sulfonate salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide. This salt is reproducibly produced from ethyl acetate when one equivalent ethane sulfonic acid is used. The weight loss (room temperature to 150°C) is about 0.74%, and the sample melts at about 259°C and decomposes at about 22O⁰C. Its crystal structure is poor. The XRPD pattern for the ethane sulfonate salt of 4-methyl-N-[3-(4- methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)- benzamide is shown in Figure 6.

[0022] The seventh embodiment of the present invention is directed to the benzene sulfonate salt of 4-methyl-N-[3-(4-methyl-imidazol- l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide. This salt is reproducibly produced from ethyl acetate when one equivalent benzene sulfonic acid is used. The weight loss (room temperature to 25O⁰C) is about 0.63%, and the sample melts with decomposition at about 26O⁰C. Its crystal structure ranges from poor to good. The XRPD pattern for the benzene sulfonate salt of 4-methyl-N- [3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)-benzamide is shown in Figure 7.

[0023] The eighth embodiment of the present invention is directed to the p-toluene sulfonate salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoiOmethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide. This salt is reproducibly produced from ethyl acetate when one equivalent p-toluene sulfonic acid is used. The weight loss (room temperature to 150°C) is about 0.26%, and the sample melts at about 187⁰C and decomposes at about 256⁰C. Its crystal structure ranges from good to excellent. The XRPD pattern for the p-toluene sulfonate salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide is shown in Figure 8.

[0024] Another embodiment of the present invention is directed to a method of preparing a variety of crystalline salts of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide according to the following scheme:

[0025] More specifically, 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide salts are made by reacting 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide free base with an acid of formula HB in a solvent. Such reaction is typically conducted in two steps, though it is within the scope of this invention to simply combine both the free base and the acid in the solvent at the same time.

[0026] In a first step, 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromemyl-phenyl]-3- (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base is dissolved or suspended in an appropriate amount of solvent at an appropriate temperature. Solvents suitable for use in the present invention include, without limitation, methanol, ethanol, 2-propanol, acetone, ethyl acetate, acetonitrile, tetrahydrofuran and combinations thereof. It is within the skill of one of ordinary skill in the art to determine suitable amounts of base to be used, as well as suitable reaction temperatures.

[0027] In a second step of the present inventive method, the 4-methyl-N-[3-(4-methyl- imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base is treated with an appropriate acid of the formula HB. Given the pKa values for 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluorometliyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide free base of 5.1 and 3.9, salt forming acids with a pKa of <3.1 have the potential to form stable crystalline salts therewith. Suitable acids include, without limitation, inorganic acids such as hydrochloric acid, phosphoric acid, sulfuric acid, and sulfonic acid and organic acids such as methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid, p-toluene sulfonic acid, citric acid, fumaric acid, gentisic acid, malonic acid, maleic acid, and tartaric acid.

[0028] In optional steps of the present inventive method, the 4-methyl-N-[3-(4-methyl- imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide salt is isolated by filtration or some other suitable means and the isolated salt is dried to remove residual solvent. In a preferred embodiment of this invention, the hydrochloride salt is first obtained as a methanol solvate which must be exposed to moisture in order to convert to the monohydrate hydrochloride salt.

[0029] A particularly preferred embodiment of the present invention is directed to a method of preparing 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin- 3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride monohydrate comprising the steps of:

(a) combining 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3- (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and hydrochloric acid in methanol under a nitrogen atmosphere;

(b) heating the reaction mixture to a temperature ranging from about 42-50°C;

(c) stirring the reaction mixture;

(d) filtering the reaction mixture while maintaining the temperature above 40⁰C to obtain a clear solution;

(e) cooling the clear solution to about 30⁰C while stirring under nitrogen atmosphere;

(f) seeding the solution;

(g) cooling the seeded solution to about 23°C; (h) stiπing the solution to obtain a suspension; (i) cooling the suspension to about -10⁰C; (j) stirring the suspension;

(k) filtering solids;

(1) rinsing solids with cold methanol; and

(m) drying the solids at about 50-55°C and 10-20 torr to obtain 4-methyl-N-[3-(4- methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)-benzamide monohydrochloride monohydrate salt.

In more preferred embodiments, stirring is conducted for about 15 minutes in step (c), cooling is accomplished over a period of about 30 minutes in step (e), cooling is accomplished over a period of about 45 minutes in step (g), stirring is conducted for about 3 hours in step (h), cooling is accomplished over a period of about 1.5 hours in step (i), stirring is conducted for about 30 minutes in step (j), the cold methanol of step (1) has a temperature of about -10°C, and/or drying is accomplished over a period of about 8-16 hours.

[0030] The tenth embodiment of the present invention is directed to a pharmaceutical composition comprising:

[0031] A "therapeutically effective amount" is intended to mean the amount of the inventive salt that, when administered to a subject in need thereof, is sufficient to effect treatment for disease conditions alleviated by the inhibition of protein kinase activity. The amount of a given compound of the invention that will be therapeutically effective will vary depending upon factors such as the disease condition and the severity thereof, the identity of the subject in need thereof, etc., which amount may be routinely determined by artisans of ordinary skill in the art.

[0032] The at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient can readily be selected by one of ordinary skill in the art and will be determined by the desired mode of administration. Illustrative examples of suitable modes of administration include oral, nasal, parenteral, topical, transdermal, and rectal. The pharmaceutical compositions of this invention may take any pharmaceutical form recognizable to the skilled artisan as being suitable. Suitable pharmaceutical forms include solid, semisolid, liquid, or lyophilized formulations, such as tablets, powders, capsules, suppositories, suspensions, liposomes, and aerosols.

[0033] The eleventh embodiment of the present invention is directed to a method of treating a disease which responds to an inhibition of protein kinase activity comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide. As noted above, illustrative modes of administration include oral, nasal, parenteral, topical, transdermal, and rectal. Administration of the crystalline form may be accomplished by administration of a pharmaceutical composition of the ninth embodiment of the invention or via any other effective means.

[0034] Specific embodiments of the invention will now be demonstrated by reference to the following examples. It should be understood that these examples are disclosed solely by way of illustrating the invention and should not be taken in any way to limit the scope of the present invention.

Example 1 Preparation of Monohydrochloride M onohydrate Salt

AMN107 AMN107 HCI H₂O salt

[0035] A l L, 4-neck, round-bottom flask equipped with a mechanical stirrer, a thermometer, heating/cooling capacity, and an addition funnel was charged in sequence with 4-methyl-N- [3-(4-methyl-imidazol-l-yl)-5-tπfluoiOmethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)-benzamide free base (10 g), methanol (250 mL), and 37% hydrochloric acid (1.85 g) under nitrogen purge. The mixture was heated to 42-5O⁰C and stirred for an additional 15 minutes. The resulting solution was filtered through a polypropylene pad, while maintaining the batch temperature above 40⁰C. The clear solution was transferred under nitrogen atmosphere to another 1 L, 4-neck, and round-bottom flask equipped with a mechanical stirrer, a thermometer, and heating/cooling capacity. The batch was stirred and cooled to 30⁰C over a period of 30 minutes. Seeds (20 mg) were added at this temperature, and the batch was cooled to 23°C over a period of 45 minutes. The batch was stirred for an additional 3 hours to obtain a thick white suspension. The suspension was cooled to -1O⁰C over a period of 1.5 hours and stirred for an additional 30 minutes. Any solid was collected by filtration and rinsed with cold (-10⁰C) methanol (20 mL). The solid was dried at 50-55°C/10-20 torr for 8-16 hours to obtain 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride monohydrate salt (9.8 g) as a white solid.

[0036] ¹H NMR 300 MHz, DMSO-d₆), δ 10.9 (s, IH), 9.58 (s, IH), 9.29 (s, IH), 9.20 (s, IH), 8.70 (d, IH), 8.63 (s, IH), 8.55 (d, IH), 8.49 (d, IH), 8.32 (d, 2H), 8.00 (s, IH), 7.91 (s, IH), 7.84 (d, IH), 7.56-7.44 (m, 3H), 2.50 (s, 3H), 2.35 (s, 3H); x-ray diffraction pattern showing maxima at 2Θ = 7.4°, 9.4°, 11.6°, 12.1°, 15.8°, 19.3°, 19.6°, 22.1°, 24.1°, 25.7°.

Example 2 Preparation of Monophosphate Salt

H₃PO₄

AMN107 AMN107 H₃PO₄ salt

[0037] To a 1 L round-bottom flask equipped with a mechanical stirrer, a thermometer, and a condenser, 4 g of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-ρhenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and 500 mL of methanol were charged. The slurry was stirred and heated to 64⁰C and held at that temperature for -30 minutes. To the resulting clear solution, 7.5 mL of 1 M phosphorous acid solution (in methanol) was added. The mixture was stirred at 64°C for one hour, cooled down to room temperature by natural cooling (cooling rate ~0.5°C/min) and held at room temperature for 3-4 hours. The solid was collected by filtration and was dried at 50-55°C/10-20 torr for 8-16 hours to obtain 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-tiifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide monophosphate salt (3.25 g) as a white solid. Melting point = ~208°C (dec); x-ray diffraction pattern showing maxima at 2Θ = 6.1°, 7.5°, 9.1°, 15.8°, 17.5°, 18.3°, 21.8°, 23.1°, 24.9°, 26.6°.

Example 3 Preparation of Methane Sulfonate Salt

ethyl acetate

AMN107 AMN107 mesylate salt

[0038] To a 75 niL reactor equipped with a temperature probe and a condenser, 307 mg of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide free base and 30 mL of ethyl acetate were charged. The slurry was stirred and heated to 76⁰C. To the solution, 580 μL of 1 M methane sulfonic acid solution (in ethyl acetate) was added. The mixture was stirred at 76°C for six hours, cooled to 25°C at a rate of 0.5°C/minute and held at 25⁰C overnight. The solid was collected by filtration and was dried at 50-55°C/10-20 torr for 8-16 hours to obtain 4-methyl-N-[3-(4- methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)- benzamide mesylate salt (-250 mg) as a yellowish solid. X-ray diffraction pattern showing maxima at 2Θ = 7.7°, 10.1°, 20.3°, 26.2°.

Example 4 Preparation of Benzylsulfonate Salt

Ethyl Acetate

AWIN107 AMN107 benzylsulfonate salt

[0039] To a 1 L round-bottom flask equipped with a mechanical stirrer, a thermometer, and a condenser, 4 g of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and 500 mL of ethyl acetate were charged. The slurry was stirred and heated to 76⁰C (reflux) and held at that temperature for 40 minutes. To the resulting clear solution, 7.5 niL of 1 M benzene sulfonic acid solution (in ethyl acetate) was added. The mixture was stirred at 76°C for 5 hours, cooled down to room temperature by natural cooling (cooling rate ~0.5°C/min) and held at room temperature for ~1 hour. The solid was collected by filtration and was dried at 50-55°C/10-20 torr for 8-16 hours to obtain 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide mono benzyl sulfonate salt as a yellowish solid. Melting point = ~260°C; x-ray diffraction pattern showing maxima at 2Θ = 6.5°, 7.8°, 9.4°, 10.4°, 13.7°, 17.0°, 17.5°, 17.9°, 18.8°, 21.2°.

Example 5 Preparation of p-Toluene Sulfonate Salt

AMN107

AMN107 p-tolysulfonate salt

[0040] To a 75 mL reactor equipped with a temperature probe and a condenser, 305.6 mg of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylammo)-benzamide free base and 30 mL of ethyl acetate were charged. The slurry was stirred and heated to 76⁰C. To the solution, 580 μL of 1 M p-toluene sulfonic acid solution (in ethyl acetate) was added. The mixture was stirred at 76⁰C for six hours, cooled to 25 °C at a rate of 0.5°C/minute and held at 25°C overnight. The solid was collected by filtration and was dried at 50-55°C/10-20 torr for 8-16 hours to obtain 4-methyl-N-[3-(4- methyl-imidazol-l-yl)-5-trifluoiOmethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)- benzamide p-toluene sulfonate salt (-250 mg) as a white solid. Melting point = -187⁰C; x-ray diffraction pattern showing maxima at 2Θ = 7.3°, 15.4°, 16.1°, 17.5°, 18.3°, 19.0°, 19.7°, 22.5°.

Example 6 Hydrochloride Salt

[0041] 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide free base and about 400 mL methanol are charged into a flask. While stirring, 744.4 mg of 37% HCl solution is added dropwise. The slurry becomes clear. The solution is stirred for 30 minutes. The solution is concentrated to 100 mL. The solution is then stirred for 2 hours; a slurry is obtained. The slurry is filtered and dried under house vacuum overnight at 50°C. Polymorphic form B is obtained with a yield of about 72.6%.

Example 7

[0042] About 50-60 mg of form A of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base was suspended in 0.75 mL of a listed solvent. The stoichiometric amount of a noted acid was subsequently added to the suspension. For inorganic acids, the mixture was stirred at ambient temperature for about 5 hours, and for sulfonic acids, it was stirred at 50⁰C overnight. Solids were collected by filtration and analyzed by XRPD and NMR.

Table 1. Formation of Hydrochloride Salt

* excellent = when main peaks are sharp and their intensities above 70 counts good = when main peaks are sharp and their intensities within 30-70 counts

Table 2. Formation of Sulfate Salt

* good = when main peaks are sharp and their intensities within 30-70 counts poor = when main peaks are broad and their intensities below 30 counts; could be amorphous salt and free base form A Table 3. Formation of Methane Sulfonate Salt

* poor = when main peaks are broad and their intensities below 30 counts

Table 4. Formation of Ethane Sulfonate Salt

* good = when main peaks are sharp and their intensities within 30-70 counts poor = when main peaks are broad and their intensities below 30 counts

[0043] The ethane sulfonate salt from acetone has an x-ray diffraction pattern showing maxima at 2Θ = 6.6°, 7.9°, 9.5°, 14.2°, 17.8°.

Table 5. Formation of Benzene Sulfonate Salt

poor = when main peaks are broad and their intensities below 30 counts

Table 6. Formation of p-Toluene Sulfonate Salt

good = when main peaks are sharp and their intensities within 30-70 counts Example 8

[0044] About 300-310 mg of form B of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base was suspended in 9 mL of 2-propanol for HCl and 15 mL acetone for the sulfonic acids. The stoichiometric amount of the noted acid was subsequently added to the suspension. For HCl, the mixture was stirred at ambient temperature for 5 hours, and for sulfonic acids, it was stirred at 50°C overnight. Then, the mixture was cooled to ambient temperature, collected by filtration and analyzed by XRPD and NMR.

Table 7.

Example 9

[0045] About 100 mg of form B of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5- trifluorometliyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base was suspended in 15 mL of methanol for the inorganic acids and in 15 mL THF for the sulfonic acids noted below. The stoichiometric amount of the listed acid was subsequently added to the suspension, except for H₃PO₄, for which two equivalents were added. The solution was stirred at 5O⁰C for about 5 hours and then cooled to ambient temperature. Solids were collected by filtration if slurry formed; otherwise, a slow N₂ flow was applied to evaporate some solvent to yield thicker slurry for filtration. The solids were analyzed by XRPD and NMR.

Table 8.

[0046] Elemental analysis was used to check salt formation for the diphosphate salt. The results are as follows:

Table 9.

Example 10

[0047] About 100 mg of form B of 4-methyl-N-[3-(4-metliyl-imidazol-l-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base was suspended in 15 mL of methanol for HCl and H₂SO₄ and in 15 mL of ethyl acetate for methane sulfonic acid. The listed amount of the listed acid was subsequently added to the suspension. The solution was stirred at ambient temperature (HCl) or 50⁰C (H₂SO₄ and methane sulfonic acid). The solids were obtained by evaporating solvent to dryness using a slow N₂ flow and analyzed by XRPD and NMR.

Table 10.

Example 11

[0048] About 300 mg of form B of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base was suspended in 30 mL of methanol for the inorganic acids and in 30 mL ethyl acetate for the sulfonic acids. The suspension was heated to reflux temperature -64°C for methanol and 76°C for ethyl acetate. The stoichiometric amount of the listed acid, dissolved in the corresponding solvent, was subsequently added to the solution. The solution was stirred under reflux for 5 hours and then cooled to ambient temperature. The solid was collected by filtration and analyzed by XRPD. Table 11.

Thermal Behavior

[0049] The LOD and decomposition temperature of the salts of the invention were determined by TGA, and the melting point was determined by DSC.

Table 12.

* The decomposition temperature was determined by the onset of the first derivative of the sample weight loss v. temperature of TGA data

Hvgroscopicity

[0050] The hygroscopicity of the salts of the invention was determined by TGA after one day at ambient temperature and 93% relative humidity. Table 13.

[0051] It should be noted that, upon further testing, hygroscopicity results have varied. At least with regard to the hydrochloride salt, moisture is lost too quickly upon testing to capture the true value; such may be true for the other salts as well.

Solubility

[0052] The solubility of the salts of the invention was determined in pH 6.8, pH 3.0 and pH 1.0 buffers by suspending 1-5 mg of each salt in 10 mL of corresponding aqueous solution. The samples were allowed to equilibrate at ambient temperature for at least 20 hours for pH 6.8 and 3.0 or about 5 hours for pH 1.0. The supernatant was filtered and used for the solubility determination by UV-VIS spectroscopy. The solid residue was analyzed by XRPD.

Table 14.

Comparative Testing

[0053] The stability of both 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base (form B) and 4-methyl- N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)-benzamide monohydrate hydrochloride salt (form B) were evaluated as described below.

Table 15.

I suspension * clear solution after stress test

A no change of color B slight discoloration

Mixture 1 : 30% 4-methyl-N-[3-(4-methyI-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide (free base or salt), 63% lactose 100 mesh/lactose 200 mesh (50:50), 5% crosprovidone, 1% Aerosil 200, 1% magnesium stearate

Mixture 2: 30% 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamide (free base or salt), 34% mannitol 60, 34% Avicel PH102, 1% Aerosil 200, 1% magnesium stearate (% by weight of free base or salt) Table 16. Forced Decomposition Test

[0054] The chemical, physicochemical and morphic characteristics of both 4-methyl-N-[3- (4-methyl-imidazol-l-yl)-5-trifluorornethyl-phenyl]-3-(4-pyridin-3-yl-pyrirnidin-2-ylamino)- benzamide free base (form B) and 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrate hydrochloride salt (form B) were evaluated as described below.

[0055] Determination of Approximate Solubility: A weighted amount (20-50 mg) of sample was charged into 2 mL of the solvent. The obtained slurry was allowed to equilibrate for 24 hours at room temperature and then filtered. The concentration of DS in saturated filtrate was measured by either UV or HPLC.

[0056] Intrinsic Dissolution Rate (IDR): Dissolution rate measurements were performed at 37⁰C using the rotating disk method (VanKell Instrument). A single rotation speed of 200 rpm was used. For IDR in 0.1 N HCl, an 800 mL volume, and for IDR in water, a 200 mL volume were used. The solution was continuously pumped through a UV measuring cell and recycled to the dissolution vessel. [0057] Hygroscopicity: Sorption/desorption isotherms were collected using a Surface Measurements Systems dynamic vapor sorption device (DVS-I). The measurements were carried out at 25°C.

[0058] While the invention has been described above with reference to specific embodiments thereof, it is apparent that many changes, modifications, and variations can be made without departing from the inventive concept disclosed herein. Accordingly, it is intended to embrace all such changes, modifications, and variations that fall within the spirit and broad scope of the appended claims. All patent applications, patents, and other publications cited herein are incorporated by reference in their entirety.

Claims

WHAT IS CLAIMED IS:

1. A salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide.

2. The salt of Claim 1, wherein the salt is a hydrochloride salt of 4-methyl-N-[3-(4- rnethyl- imidazol- 1-yl)- 5-trifluoromethyl-phenyl] -3 -(4-ρyridin-3 -yl-pyrimidm-2-ylamino)- benzamide.

3. The salt of Claim 2, wherein the salt is 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride monohydrate.

4. The salt of Claim 1, wherein the salt is a monophosphate salt of 4-methyl-N-[3-(4- methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)- benzamide.

5. The salt of Claim 1, wherein the salt is a diphosphate salt of 4-methyl-N-[3-(4-methyl- imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide.

6. The salt of Claim 1, wherein the salt is a sulfate salt of 4-methyl-N-[3-(4-methyl- imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide.

7. The salt of Claim 1, wherein the salt is a methane sulfonate salt of 4-methyl-N-[3-(4- methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)- benzamide.

8. The salt of Claim 1, wherein the salt is an ethane sulfonate salt of 4-methyl-N-[3-(4- methyl-imidazol-l-yl)-5-trifluoiOmethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)- benzamide.

9. The salt of Claim 1, wherein the salt is a benzene sulfonate salt of 4-methyl-N-[3-(4- methyl-imidazol-l-yl)-5-trifluorometliyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)- benzamide.

10. The salt of Claim 1, wherein the salt is a p-toluene sulfonate salt of 4-methyl-N-[3-(4- methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylammo)- benzamide.

11. A method of preparing a salt of 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide comprising the step of: reacting 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4- pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base with an acid of formula HB in a solvent.

12. The method of Claim 11, wherein the acid is selected from the group consisting of hydrochloric acid, phosphoric acid, sulfuric acid, sulfonic acid, methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid, p-toluene sulfonic acid, citric acid, fumaric acid, gentisic acid, malonic acid, maleic acid, and tartaric acid.

13. A method of preparing 4-methyl-N-[3-(4-methyl-imidazol-l-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride monohydrate comprising the steps of:

(a) combining 4-methyl-N-[3-(4-methyl-imidazol- l-yl)-5-trifluoromethyl-phenyl]-3- (4-pyridin-3-yl-pyrirnidin-2-ylamino)-benzamide free base and hydrochloric acid in methanol under a nitrogen atmosphere;

(b) heating the reaction mixture to a temperature ranging from about 42-50⁰C;

(c) stirring the reaction mixture;

(d) filtering the reaction mixture while maintaining the temperature above 4O⁰C to obtain a clear solution;

(f) seeding the solution;

(g) cooling the seeded solution to about 23°C; (h) stining the solution to obtain a suspension; (i) cooling the suspension to about -10⁰C;

(j) stirring the suspension; (k) filtering solids;

(1) rinsing solids with cold methanol; and

14. A pharmaceutical composition comprising:

(a) a therapeutically effective amount of a salt according to claim 1; and

15. The pharmaceutical composition of Claim 14, wherein the salt is 4-methyl-N-[3-(4- methyl-imidazol-l-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)- benzamide monohydrochloride monohydrate.

16. A method of treating a disease which responds to an inhibition of protein kinase activity comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a salt according to Claim 1.

17. The method of Claim 16, wherein the salt is 4-methyl-N-[3-(4-methyl-imidazol-l-yl)- 5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride monohydrate.